This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    B5091007
Previous Study | Return to List | Next Study

Clostridium Difficile Vaccine Efficacy Trial (Clover)

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by Pfizer
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT03090191
First received: March 20, 2017
Last updated: June 29, 2017
Last verified: June 2017
  Purpose

The Clover trial is evaluating an investigational vaccine that may help to prevent Clostridium difficile infection. Participants in the study are adults 50 years of age and older, who are at risk of developing Clostridium difficile infection. The study will assess whether the vaccine prevents the disease, and whether it is safe and well tolerated.

Each subject will receive 3 doses of Clostridium difficile vaccine or placebo and be followed for up to 3 years after vaccination for potential Clostridium difficile infection.


Condition Intervention Phase
Clostridium Difficile Infection Biological: Clostridium difficile vaccine Biological: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Prevention
Official Title: A Phase 3, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • First primary case CDI incidence [ Time Frame: Up to 3 years after the 3rd dose ]
    Per 1000 person-years of follow-up (confirmed at the central laboratory)

  • First primary case CDI incidence [ Time Frame: Up to 3.4 years after the 2nd dose ]
    Per 1000 person-years of follow-up (confirmed at the central laboratory)

  • Percentage of subjects reporting local reactions [ Time Frame: Up to 7 days following each vaccination, 1, 2, and 3 ]
    Pain, erythema, and induration, as self-reported on electronic diaries

  • Percentage of subjects reporting systemic events [ Time Frame: Up to 7 days following each vaccination, 1, 2, and 3 ]
    Fever, vomiting, headache, fatigue, new or worsening muscle pain, and new or worsening joint pain, as self-reported on electronic diaries

  • Percentage of subjects reporting nonserious adverse events [ Time Frame: Up to 7 months after the first dose ]
    As elicited by investigational site staff

  • Percentage of subjects reporting serious adverse events [ Time Frame: Up to 12 months after the first dose ]
    As elicited by investigational site staff


Secondary Outcome Measures:
  • Recurrent case CDI incidence [ Time Frame: Up to 3 years after the 3rd dose ]
    Per 1000 person-years of follow-up (confirmed at the central laboratory)

  • Recurrent case CDI incidence [ Time Frame: Up to 3.4 years after the 2nd dose ]
    Per 1000 person-years of follow-up (confirmed at the central laboratory)

  • First primary case CDI incidence [ Time Frame: Up to 3 years after the 3rd dose ]
    Per 1000 person-years of follow-up (including local laboratory demonstration of the presence of Clostridium difficile)

  • First primary case CDI incidence [ Time Frame: Up to 3.4 years after the 2nd dose ]
    Per 1000 person-years of follow-up (including local laboratory demonstration of the presence of Clostridium difficile)

  • Recurrent case CDI incidence [ Time Frame: Up to 3 years after the 3rd dose ]
    Per 1000 person-years of follow-up (including local laboratory demonstration of the presence of Clostridium difficile)

  • Recurrent case CDI incidence [ Time Frame: Up to 3.4 years after the 2nd dose ]
    Per 1000 person-years of follow-up (including local laboratory demonstration of the presence of Clostridium difficile)

  • In subjects that receive only 2 doses, first primary CDI incidence [ Time Frame: Up to 3.4 years after the 2nd dose ]
    Per 1000 person-years of follow-up (confirmed at the central laboratory)

  • In subjects that receive only 2 doses, recurrent case CDI incidence [ Time Frame: Up to 3.4 years after the 2nd dose ]
    Per 1000 person-years of follow-up (confirmed at the central laboratory)

  • In subjects that receive only 2 doses, first primary case CDI incidence [ Time Frame: Up to 3.4 years after the 2nd dose ]
    Per 1000 person-years of follow-up (including local laboratory demonstration of the presence of Clostridium difficile)

  • In subjects that receive only 2 doses, recurrent case CDI incidence [ Time Frame: Up to 3.4 years after the 2nd dose ]
    Per 1000 person-years of follow-up (including local laboratory demonstration of the presence of Clostridium difficile)

  • All case CDI incidence [ Time Frame: Up to 3 years after the 3rd dose ]
    Per 1000 person-years of follow-up (confirmed at the central laboratory)

  • All case CDI incidence [ Time Frame: Up to 3 years after the 3rd dose ]
    Per 1000 person-years of follow-up (including local laboratory demonstration of the presence of Clostridium difficile)

  • All case CDI incidence [ Time Frame: Up to 3.4 years after the 2nd dose ]
    Per 1000 person-years of follow-up (confirmed at the central laboratory)

  • All case CDI incidence [ Time Frame: Up to 3.4 years after the 2nd dose ]
    Per 1000 person-years of follow-up (including local laboratory demonstration of the presence of Clostridium difficile)

  • Mean time to resolution of diarrhea in first primary cases of CDI [ Time Frame: Up to 3.5 years after enrolment ]
    Confirmed at the central laboratory

  • Proportion of subjects experiencing a first primary episode of CDI who have a non-protocol-related medically attended visit during the CDI episode [ Time Frame: Up to 3.5 years after enrolment ]
    Confirmed at the central laboratory

  • Mean ATLAS (age, treatment with systemic antibiotics during CDI therapy, leukocyte count, serum albumin, and serum creatinine) score [ Time Frame: Up to 3.5 years after enrolment ]
    Score calculated based on age, treatment with systemic antibiotics during CDI therapy, leukocyte count, serum albumin, and serum creatinine


Estimated Enrollment: 15776
Actual Study Start Date: March 29, 2017
Estimated Study Completion Date: September 28, 2020
Estimated Primary Completion Date: September 28, 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Clostridium difficile vaccine Biological: Clostridium difficile vaccine
Toxoid-based Clostridium difficile vaccine
Placebo Comparator: Placebo Biological: Placebo
Normal saline solution (0.9% sodium chloride)

  Eligibility

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Evidence of a personally signed and dated informed consent document.
  • Willing and able to comply with study procedures.
  • Subjects with an increased risk of future contact with healthcare systems or subjects who have received systemic antibiotics in the previous 12 weeks.
  • Ability to be contacted by telephone during study participation.
  • Negative urine pregnancy test for female subjects of childbearing potential.

Exclusion Criteria:

  • Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  • Participation in other studies involving investigational drug(s)/vaccine(s) within 28 days prior to study entry until 1 month after the third vaccination.
  • Previous administration of an investigational C difficile vaccine or C difficile mAb therapy.
  • Prior episode of CDI..
  • Receipt of blood products or immunoglobulins within 6 months before enrollment.
  • Subjects who may be unable to respond to vaccination due to:

    • Metastatic malignancy; or
    • End-stage renal disease; or
    • Any serious medical disorder likely to be fatal within the next 12 months; or
    • Congenital or acquired immunodeficiency; or
    • Receipt of high dose systemic corticosteroids for 14 days within 28 days of enrollment; or
    • Receipt of chronic systemic treatment with other known immunosuppressant medications, or radiotherapy, within 6 months of enrollment.
  • Known infection with human immunodeficiency virus (HIV).
  • Any bleeding disorder or anticoagulant therapy that would contraindicate intramuscular injection.
  • Any contraindication to vaccination or vaccine components, including previous anaphylactic reaction to any vaccine or vaccine-related components.
  • Prior small- or large-bowel resection.
  • Any condition or treatment resulting in frequent diarrhea.
  • Other acute or chronic condition or abnormality that may increase the risk associated with study participation or IP administration or may interfere with interpretation of study results
  • Pregnant or breastfeeding female subjects; male subjects and female subjects who are sexually active and at risk for pregnancy and will not/cannot use 2 methods of contraception
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03090191

Contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

  Show 140 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT03090191     History of Changes
Other Study ID Numbers: B5091007
2016-003866-14 ( EudraCT Number )
CLOVER ( Other Identifier: Alias Study Number )
Study First Received: March 20, 2017
Last Updated: June 29, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Information relating to our policy on data sharing and the process for requesting data can be found at the following link:

http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests

URL: http://

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Vaccines
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 19, 2017